tasisulam + sunitinib

Tasisulam + sunitinib is an experimental combination of two anticancer agents that was investigated in preclinical research studies. Tasisulam (LY573636) is a small molecule antitumor agent developed by Eli Lilly that inhibits mitotic progression and induces vascular normalization through a dual mechanism involving mitotic catastrophe and antiangiogenesis. Sunitinib (Sutent) is a multi-targeted receptor tyrosine kinase inhibitor developed by Pfizer that targets VEGFR and PDGFR. In preclinical studies, the combination significantly delayed the growth of Caki-1 renal cell carcinoma models, demonstrating synergy where monotherapy was inactive. While sunitinib is an FDA-approved therapy for several indications, the development of tasisulam was terminated by Eli Lilly in 2011 due to safety concerns and lack of efficacy in Phase II trials. There is no evidence that the tasisulam + sunitinib combination progressed into clinical development.

Other names

tasisulam sodium + sunitinib malateLY573636-sodium + sunitinib